Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Loading
Home
News
Leantime Working with Local Charlotte Software Solutions agency Kingsmen Software as a startup in their AI Lab

From Leantime

By Gloria Folaron

June 9, 2023

Leantime Working with Local Charlotte Software Solutions agency Kingsmen Software as a startup in their AI Lab

Leantime said it was collaborating with Kingsmen Software’s AI Lab in Charlotte as the company developed AI features for its open-source project and work management platform.

View original article on leantime.io

Most Recent

Timeshifter Raises New Funding to Scale Circadian Technology Across Travel, Shift Work and Healthcare

Timeshifter Raises New Funding to Scale Circadian Technology Across Travel, Shift Work and Healthcare

PR Newswire reported that Timeshifter has raised 5.3 million dollars total to date and announced a new round led by Skip Capital.

Apr 15, 2026

The 96% Blind Spot: Oso and Cyera Research reveal unused permissions lying in wait for AI agents

The 96% Blind Spot: Oso and Cyera Research reveal unused permissions lying in wait for AI agents

Oso and Cyera published joint research finding that enterprise workers leave 96% of granted permissions unused, creating AI-agent access risk.

Mar 17, 2026

American Medical Association Establishes Category III CPT Code for Procedure Associated with the Use of MuReva Phototherapy's LED-based Photobiomodulation Therapy Device

American Medical Association Establishes Category III CPT Code for Procedure Associated with the Use of MuReva Phototherapy's LED-based Photobiomodulation Therapy Device

AMA CPT Editorial Panel approved new Category III CPT code 1011T for MuReva's photobiomodulation therapy procedures

Dec 15, 2025

MuReva Phototherapy Presents Data during 2025 ASTRO Meeting Confirming Safety and Efficacy of the Company's LED-based Photobiomodulation Therapy Device

MuReva Phototherapy Presents Data during 2025 ASTRO Meeting Confirming Safety and Efficacy of the Company's LED-based Photobiomodulation Therapy Device

Study confirmed the safety and the ability of the company's LED-based photobiomodulation therapy breakthrough device technology to reduce severity of oral mucositis in patients with head and neck cancer undergoing radiation therapy

Oct 27, 2025

Similar Posts

Ex Google Maps team members get Sequoia backing to build an AI-powered collaboration board

Ex Google Maps team members get Sequoia backing to build an AI-powered collaboration board

When you talk to a chatbot like ChatGPT, Claude, or Gemini, your responses are largely linear. You often have to ask follow-up questions to get more information. For instance, when you are planning a trip, you might first ask the chatbot about the place and follow it up with questions on meal planning, activities, tips for the trip, and a packing list. A team of former Google Maps engineers is building an infinite board interface called Cove. This design should help you generate several respons

Oct 8, 2024

Leantime Launches Project Management Platform for Non-Project Managers with Neurodiversity in Mind

Leantime Launches Project Management Platform for Non-Project Managers with Neurodiversity in Mind

Leantime Launches Project Management Platform for Non-Project Managers with Neurodiversity in Mind. Leantime. August 9, 2023 4 min read.

Aug 8, 2023

Letta, one of UC Berkeley’s most anticipated AI startups, has just come out of stealth

Letta, one of UC Berkeley’s most anticipated AI startups, has just come out of stealth

A startup called Letta has just emerged from stealth with tech that helps AI models remember users and conversations. Created in UC Berkeley’s famed labs startup factory, it also announced $10 million in seed money led by Felicis’ Astasia Myers, at a $70 million post-money valuation. Letta is also backed by a who’s who of angel investors in AI, like Google’s Jeff Dean, Hugging Face’s Clem Delangue, Runway’s Cristóbal Valenzuela, and Anyscale’s Robert Nishihara, among others. Founded by Berkele

Sep 23, 2024

AllSpice’s platform is the GitHub for electrical engineering teams

AllSpice’s platform is the GitHub for electrical engineering teams

AllSpice's platform sits between existing workflow software. It allows hardware teams to collaborate on the types of documents they traditionally work in — documents that don't easily translate over Slack and email — like PCB files and electronic CAD files, both of which are used to design circuit boards. AllSpice's platform has landed customers such as Blue Origin and Bose and just raised a $15 million Series A round.

Jun 23, 2025

Most Recent

Timeshifter Raises New Funding to Scale Circadian Technology Across Travel, Shift Work and Healthcare

Timeshifter Raises New Funding to Scale Circadian Technology Across Travel, Shift Work and Healthcare

PR Newswire reported that Timeshifter has raised 5.3 million dollars total to date and announced a new round led by Skip Capital.

Apr 15, 2026

The 96% Blind Spot: Oso and Cyera Research reveal unused permissions lying in wait for AI agents

The 96% Blind Spot: Oso and Cyera Research reveal unused permissions lying in wait for AI agents

Oso and Cyera published joint research finding that enterprise workers leave 96% of granted permissions unused, creating AI-agent access risk.

Mar 17, 2026

American Medical Association Establishes Category III CPT Code for Procedure Associated with the Use of MuReva Phototherapy's LED-based Photobiomodulation Therapy Device

American Medical Association Establishes Category III CPT Code for Procedure Associated with the Use of MuReva Phototherapy's LED-based Photobiomodulation Therapy Device

AMA CPT Editorial Panel approved new Category III CPT code 1011T for MuReva's photobiomodulation therapy procedures

Dec 15, 2025

MuReva Phototherapy Presents Data during 2025 ASTRO Meeting Confirming Safety and Efficacy of the Company's LED-based Photobiomodulation Therapy Device

MuReva Phototherapy Presents Data during 2025 ASTRO Meeting Confirming Safety and Efficacy of the Company's LED-based Photobiomodulation Therapy Device

Study confirmed the safety and the ability of the company's LED-based photobiomodulation therapy breakthrough device technology to reduce severity of oral mucositis in patients with head and neck cancer undergoing radiation therapy

Oct 27, 2025

Similar Posts

Ex Google Maps team members get Sequoia backing to build an AI-powered collaboration board

Ex Google Maps team members get Sequoia backing to build an AI-powered collaboration board

When you talk to a chatbot like ChatGPT, Claude, or Gemini, your responses are largely linear. You often have to ask follow-up questions to get more information. For instance, when you are planning a trip, you might first ask the chatbot about the place and follow it up with questions on meal planning, activities, tips for the trip, and a packing list. A team of former Google Maps engineers is building an infinite board interface called Cove. This design should help you generate several respons

Oct 8, 2024

Leantime Launches Project Management Platform for Non-Project Managers with Neurodiversity in Mind

Leantime Launches Project Management Platform for Non-Project Managers with Neurodiversity in Mind

Leantime Launches Project Management Platform for Non-Project Managers with Neurodiversity in Mind. Leantime. August 9, 2023 4 min read.

Aug 8, 2023

Letta, one of UC Berkeley’s most anticipated AI startups, has just come out of stealth

Letta, one of UC Berkeley’s most anticipated AI startups, has just come out of stealth

A startup called Letta has just emerged from stealth with tech that helps AI models remember users and conversations. Created in UC Berkeley’s famed labs startup factory, it also announced $10 million in seed money led by Felicis’ Astasia Myers, at a $70 million post-money valuation. Letta is also backed by a who’s who of angel investors in AI, like Google’s Jeff Dean, Hugging Face’s Clem Delangue, Runway’s Cristóbal Valenzuela, and Anyscale’s Robert Nishihara, among others. Founded by Berkele

Sep 23, 2024

AllSpice’s platform is the GitHub for electrical engineering teams

AllSpice’s platform is the GitHub for electrical engineering teams

AllSpice's platform sits between existing workflow software. It allows hardware teams to collaborate on the types of documents they traditionally work in — documents that don't easily translate over Slack and email — like PCB files and electronic CAD files, both of which are used to design circuit boards. AllSpice's platform has landed customers such as Blue Origin and Bose and just raised a $15 million Series A round.

Jun 23, 2025